Changing Outcomes CHANGING LIVES!
Designed for first pass success with all clot types in stroke thrombectomy
Currently not available in your region.
Innovation in progress
in development…
When complexity requires simplicity
in peripheral arterial occlusion
A definitive solution
for post aSAH cerebal vasospasm
The next frontier in thrombectomy
designed to maximize clot retention
Currently not available in your region.
Engineered for Coronary Thrombectomy
retrieve large thrombus burden in coronary arterial occlusion
Aspiration Catheter
Designed for first pass success with all clot types in stroke thrombectomy
Currently not available in your region.
A definitive solution
for post aSAH cerebal vasospasm
The next frontier in thrombectomy
designed to maximize clot retention
Currently not available in your region.
Aspiration Catheter
Designed for first pass success with all clot types in stroke thrombectomy
Innovation in progress
in development…
When complexity
requires simplicity
in peripheral arterial occlusion
Currently not available in your region.
A definitive solution
for post aSAH cerebral vasospasm
The next frontier in thrombectomy
designed to maximize clot retention
Engineered for Coronary Thrombectomy
retrieve large thrombus burden in coronary arterial occlusion
Aspiration Catheter
This product is currently not available in your region
Designed for first pass success with all clot types in stroke thrombectomy
A definitive solution
for post aSAH cerebral vasospasm
The next frontier in thrombectomy
designed to maximize clot retention
Aspiration Catheter
This product is currently not available in your region
Occlusion of a brain artery
Strokes each year
Cause of severe disability
Cause of death worldwide
Due to clots
Occlusion of a heart artery
Heart attacks each year
Cause of death worldwide (CVD)
Due to clots
Occlusion of an artery anywhere in the body
Acute limb ischemia each year
Will die at year one
Will need major amputation at year one
Due to clots
“Our experience with NeVa has been fantastic, with high complete recanalization rates as of the first attempt and we’re excited to be among the first centers to use the NeVa NET.”
NHS Royal London, London, UK
“enVast could provide a new therapeutic opportunity for myocardial infarct patients with large thrombus burden, who still represent a major challenge for procedural success and long-term outcomes.”
Istituto Cardiocentro Ticino, Lugano, Switzerland
“Patients with acute limb ischemia often present a complex medical history and pose significant challenges for physicians who must navigate severely diseased arteries and work within narrow, stenotic vessels. In such cases, when access is difficult, or when working below the knee, the low profile and excellent deliverability of pVasc make it an especially valuable tool.”
Sanger Heart and Vascular Institute, Charlotte, North Carolina.
“Complete angiographic resolution of vasospasm with one pass! It’s my new go-to device for symptomatic vasospasm.”
The Ohio State University Wexner Medical Center, Columbus, Ohio
Dr Fernando Ezequiel Petra, Mendoza, Argentina
Dr Dario Bongiovanni, Augsburg, Germany; Dr Francesco Loizzi, Bari, Italy; Dr Antonio Landi and Prof Marco Valgimigli, Lugano, Switzerland
NATURE trial, a prospective randomized controlled trial comparing the safety and effectiveness of thrombectomy using enVast before conventional PCI versus…
Greg Cook joins Vesalio as Chief Commercial Officer to lead commercial strategy and execution across its thrombectomy platform.
Company advances global neuro-intervention footprint with new CE-marked devices for vasospasm and stroke, and expanded U.S. indications for aspiration catheters.
The FDA clearance of enVast redefines coronary thrombectomy treatment and further expands Vesalio’s commercial platform.
The FDA clearances expand Vesalio’s thrombectomy portfolio to support its growth strategy in the rapidly expanding multi-billion-dollar global thrombectomy market.
Vesalio Introduces pVasc™ U.S. Clinical Study to capture real-world data and optimize results for patients suffering from peripheral vascular disease.
NATURE trial, a prospective randomized controlled trial comparing the safety and effectiveness of thrombectomy using enVast before conventional PCI versus…
Greg Cook joins Vesalio as Chief Commercial Officer to lead commercial strategy and execution across its thrombectomy platform.
Company advances global neuro-intervention footprint with new CE-marked devices for vasospasm and stroke, and expanded U.S. indications for aspiration catheters.
The FDA clearance of enVast redefines coronary thrombectomy treatment and further expands Vesalio’s commercial platform.
The FDA clearances expand Vesalio’s thrombectomy portfolio to support its growth strategy in the rapidly expanding multi-billion-dollar global thrombectomy market.
Vesalio Introduces pVasc™ U.S. Clinical Study to capture real-world data and optimize results for patients suffering from peripheral vascular disease.
by removing vascular occlusions and restoring blood flow
Please select your region to enter our world of innovation:
